TEVA logo

TEVA Cash and Cash Equivalents

Annual Cash & Cash Equivalents:

$3.30B+$74.00M(+2.29%)
December 31, 2024

Summary

  • As of today, TEVA annual cash & cash equivalents is $3.30 billion, with the most recent change of +$74.00 million (+2.29%) on December 31, 2024.
  • During the last 3 years, TEVA annual cash & cash equivalents has risen by +$1.14 billion (+52.42%).
  • TEVA annual cash & cash equivalents is now -52.49% below its all-time high of $6.95 billion, reached on December 31, 2015.

Performance

TEVA Cash and Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAbalance sheet metrics

Quarterly Cash & Cash Equivalents:

$2.20B+$41.98M(+1.94%)
September 30, 2025

Summary

  • As of today, TEVA quarterly cash & cash equivalents is $2.20 billion, with the most recent change of +$41.98 million (+1.94%) on September 30, 2025.
  • Over the past year, TEVA quarterly cash & cash equivalents has dropped by -$1.12 billion (-33.62%).
  • TEVA quarterly cash & cash equivalents is now -68.54% below its all-time high of $7.00 billion, reached on June 30, 2016.

Performance

TEVA Quarterly Cash & Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAbalance sheet metrics

Cash and Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

TEVA Cash and Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1Y1 Year+2.3%-33.6%
3Y3 Years+52.4%-1.0%
5Y5 Years+67.1%+20.6%

TEVA Cash and Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs Low
3Y3-Yearat high+52.4%-33.6%+29.8%
5Y5-Yearat high+67.1%-33.6%+29.8%
All-TimeAll-Time-52.5%>+9999.0%-68.5%>+9999.0%

TEVA Cash and Cash Equivalents History

DateAnnualQuarterly
Sep 2025
-
$2.20B(+1.9%)
Jun 2025
-
$2.16B(+27.3%)
Mar 2025
-
$1.70B(-48.6%)
Dec 2024
$3.30B(+2.3%)
$3.30B(-0.6%)
Sep 2024
-
$3.32B(+47.0%)
Jun 2024
-
$2.26B(-24.5%)
Mar 2024
-
$2.99B(-7.3%)
Dec 2023
$3.23B(+15.2%)
$3.23B(+43.4%)
Sep 2023
-
$2.25B(-15.7%)
Jun 2023
-
$2.67B(+24.5%)
Mar 2023
-
$2.14B(-23.5%)
Dec 2022
$2.80B(+29.4%)
$2.80B(+25.9%)
Sep 2022
-
$2.22B(+8.1%)
Jun 2022
-
$2.06B(-5.4%)
Mar 2022
-
$2.18B(+0.5%)
Dec 2021
$2.17B(-0.6%)
$2.17B(+5.9%)
Sep 2021
-
$2.05B(-16.1%)
Jun 2021
-
$2.44B(+39.8%)
Mar 2021
-
$1.74B(-19.9%)
Dec 2020
$2.18B(+10.2%)
$2.18B(+19.2%)
Sep 2020
-
$1.83B(-23.9%)
Jun 2020
-
$2.40B(+33.1%)
Mar 2020
-
$1.80B(-8.7%)
Dec 2019
$1.98B(+10.8%)
$1.98B(+59.1%)
Sep 2019
-
$1.24B(-42.7%)
Jun 2019
-
$2.16B(+9.7%)
Mar 2019
-
$1.97B(+10.7%)
Dec 2018
$1.78B(+85.0%)
$1.78B(-6.1%)
Sep 2018
-
$1.90B(+1.0%)
Jun 2018
-
$1.88B(+31.2%)
Mar 2018
-
$1.43B(+46.2%)
Dec 2017
$963.00M(-2.5%)
$980.01M(+39.0%)
Sep 2017
-
$705.01M(+14.4%)
Jun 2017
-
$616.01M(-32.5%)
Mar 2017
-
$911.99M(-45.6%)
Dec 2016
$988.00M(-85.8%)
$1.68B(+7.1%)
Sep 2016
-
$1.57B(-77.6%)
Jun 2016
-
$7.00B(+16.7%)
Mar 2016
-
$6.00B(-13.7%)
Dec 2015
$6.95B(+212.0%)
$6.96B(+630.0%)
Sep 2015
-
$952.99M(-13.9%)
Jun 2015
-
$1.11B(-69.2%)
Mar 2015
-
$3.59B(+50.1%)
Dec 2014
$2.23B(+114.5%)
$2.39B(+56.7%)
Sep 2014
-
$1.53B(+60.2%)
Jun 2014
-
$954.00M(+4.4%)
Mar 2014
-
$914.00M(-14.4%)
Dec 2013
$1.04B(-63.9%)
$1.07B(-9.0%)
Sep 2013
-
$1.17B(-8.7%)
Jun 2013
-
$1.29B(-9.1%)
Mar 2013
-
$1.41B(-51.2%)
Dec 2012
$2.88B(+162.7%)
$2.90B(+97.3%)
Sep 2012
-
$1.47B(+20.6%)
Jun 2012
-
$1.22B(+10.5%)
Mar 2012
-
$1.10B(-1.0%)
Dec 2011
$1.10B
$1.11B(-5.8%)
Sep 2011
-
$1.18B(-0.7%)
DateAnnualQuarterly
Jun 2011
-
$1.19B(+50.1%)
Mar 2011
-
$793.00M(-39.1%)
Dec 2010
$1.25B(-37.4%)
$1.30B(+25.5%)
Sep 2010
-
$1.04B(-78.8%)
Jun 2010
-
$4.89B(+81.1%)
Mar 2010
-
$2.70B(+19.9%)
Dec 2009
$2.00B(+7.6%)
$2.25B(+20.8%)
Sep 2009
-
$1.86B(-1.8%)
Jun 2009
-
$1.90B(-20.7%)
Mar 2009
-
$2.39B(+24.3%)
Dec 2008
$1.85B(+24.6%)
$1.92B(-41.5%)
Jun 2008
-
$3.29B(+2.5%)
Mar 2008
-
$3.21B(+11.6%)
Dec 2007
$1.49B(+11.7%)
$2.88B(+8.2%)
Sep 2007
-
$2.66B(-0.3%)
Jun 2007
-
$2.67B(+13.8%)
Mar 2007
-
$2.34B(+14.5%)
Dec 2006
$1.33B(+4.4%)
$2.05B(+22.2%)
Sep 2006
-
$1.67B(+28.0%)
Jun 2006
-
$1.31B(+0.2%)
Mar 2006
-
$1.31B(-41.0%)
Dec 2005
$1.28B(+62.8%)
$2.21B(+71.1%)
Sep 2005
-
$1.29B(+6.9%)
Jun 2005
-
$1.21B(+15.4%)
Mar 2005
-
$1.05B(+0.8%)
Dec 2004
$784.00M(-25.8%)
$1.04B(-8.5%)
Sep 2004
-
$1.14B(+23.6%)
Jun 2004
-
$920.21M(-0.2%)
Mar 2004
-
$922.28M(-33.1%)
Dec 2003
$1.06B(+30.5%)
$1.38B(+22.6%)
Sep 2003
-
$1.13B(+7.6%)
Dec 2002
$809.90M(+5.3%)
$1.05B(+81.0%)
Jun 2002
-
$577.60M(-11.7%)
Mar 2002
-
$653.80M(-15.0%)
Dec 2001
$768.92M(+82.8%)
$768.92M(-4.3%)
Sep 2001
-
$803.30M(+139.0%)
Jun 2001
-
$336.09M(-4.8%)
Mar 2001
-
$353.06M(-16.1%)
Dec 2000
$420.63M(+445.0%)
$420.63M(+350.3%)
Jun 2000
-
$93.41M(-13.7%)
Mar 2000
-
$108.25M(+94.0%)
Dec 1999
$77.18M(+63.9%)
-
Dec 1998
$47.10M(-7.5%)
-
Sep 1998
-
$55.80M(-41.4%)
Jun 1998
-
$95.30M(+56.5%)
Mar 1998
-
$60.90M(+19.6%)
Dec 1997
$50.90M(-16.8%)
$50.90M(-16.8%)
Dec 1996
$61.20M(-5.7%)
$61.20M(-5.7%)
Dec 1995
$64.90M(+53.1%)
$64.90M(+53.1%)
Dec 1994
$42.40M(+6.3%)
$42.40M(+6.3%)
Dec 1993
$39.90M(+189.1%)
$39.90M(+189.1%)
Dec 1992
$13.80M(+74.7%)
$13.80M(+74.7%)
Dec 1991
$7.90M(-48.7%)
$7.90M(-48.7%)
Dec 1990
$15.40M(+234.8%)
$15.40M(+234.8%)
Dec 1989
$4.60M(-64.9%)
$4.60M(-64.9%)
Dec 1988
$13.10M(-17.6%)
$13.10M(-17.6%)
Mar 1987
$15.90M(-29.0%)
$15.90M(-29.0%)
Mar 1986
$22.40M
$22.40M

FAQ

  • What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents?
  • What is the all-time high annual cash & cash equivalents for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents year-on-year change?
  • What is Teva Pharmaceutical Industries Limited quarterly cash & cash equivalents?
  • What is the all-time high quarterly cash & cash equivalents for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited quarterly cash & cash equivalents year-on-year change?

What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents?

The current annual cash & cash equivalents of TEVA is $3.30B

What is the all-time high annual cash & cash equivalents for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high annual cash & cash equivalents is $6.95B

What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents year-on-year change?

Over the past year, TEVA annual cash & cash equivalents has changed by +$74.00M (+2.29%)

What is Teva Pharmaceutical Industries Limited quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of TEVA is $2.20B

What is the all-time high quarterly cash & cash equivalents for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high quarterly cash & cash equivalents is $7.00B

What is Teva Pharmaceutical Industries Limited quarterly cash & cash equivalents year-on-year change?

Over the past year, TEVA quarterly cash & cash equivalents has changed by -$1.12B (-33.62%)
On this page